Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C

The latest drug development news and highlights from our FDA Performance Tracker.

Novel agent submissions took center stage in the past week, thanks to applications for Sanofi and Regeneron Pharmaceuticals Inc.'s dupilumab for atopic dermatitis, an indication that has already received a breakthrough therapy designation, and Biogen Inc. and Ionis Pharmaceuticals Inc.'s nusinersen, which could be the first drug to treat spinal muscular atrophy. Here's your news in brief:

AbbVie Inc. submitted a supplemental new drug application (sNDA) for a new indication for Imbruvica for treatment of marginal...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet